舒尼替尼（由辉瑞研发，商标名索坦）是一种口服的小分子多靶点受体酪氨酸激酶抑制剂，2006年1月26日被FDA批准用于治疗对标准疗法没有响应或不能耐受的胃肠道基质肿瘤和转移性肾细胞癌。舒尼替尼是第一种被批准用于同时治疗两种类型癌症的药物。

Sunitinib (marketed as Sutent by Pfizer, and previously known as SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications.